Key Highlights
- Comprehensive Preclinical Services: SERI’s expertise enhances Ora’s research capabilities, ensuring precision in preclinical evaluations.
- Unmatched Breadth of Models: Access to unique ocular safety and efficacy models supports advanced ophthalmic research.
- Expanded Capacity: The partnership expands Ora’s research offerings and accelerates the development of new therapies.
Source: Business Wire
Notable Quotes
- “By combining our strengths, we are poised to accelerate the development of innovative therapies at all stages, furthering SERI’s mission as a global center of excellence.” – Stuart Abelson, Chairman & CEO at Ora, Inc
- “This collaboration propels us toward realizing SERI’s vision of becoming an international center of excellence in eye and vision research.” – Professor Jodhbir Mehta, MD, Executive Director at SERI
SoHC's Take
The collaboration between Ora, Inc. and the Singapore Eye Research Institute marks a pivotal shift in ophthalmology research, focusing on innovative preclinical studies. This alliance not only promises to advance the development of new therapies but also sets a benchmark for global research collaborations in the medical field. The partnership leverages SERI’s cutting-edge resources and Ora’s comprehensive network to provide unprecedented support for ophthalmic innovation, promising substantial advancements in the treatment of eye diseases worldwide.
